Market capitalization | $311.18m |
Enterprise Value | $176.68m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1,104.25 |
P/S ratio (TTM) P/S ratio | 1,944.88 |
P/B ratio (TTM) P/B ratio | 2.29 |
Revenue growth (TTM) Revenue growth | -85.98% |
Revenue (TTM) Revenue | $160.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Chimerix, Inc. forecast:
5 Analysts have issued a Chimerix, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.16 0.16 |
86%
86%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -93 -93 |
3%
3%
|
EBIT (Operating Income) EBIT | -93 -93 |
3%
3%
|
Net Profit | -84 -84 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Head office | United States |
CEO | Michael Andriole |
Employees | 72 |
Founded | 2000 |
Website | www.chimerix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.